These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival. Shin SH; Kim SC; Hong SM; Kim YH; Song KB; Park KM; Lee YJ Pancreas; 2013 Mar; 42(2):216-22. PubMed ID: 23344532 [TBL] [Abstract][Full Text] [Related]
4. Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Embuscado EE; Laheru D; Ricci F; Yun KJ; de Boom Witzel S; Seigel A; Flickinger K; Hidalgo M; Bova GS; Iacobuzio-Donahue CA Cancer Biol Ther; 2005 May; 4(5):548-54. PubMed ID: 15846069 [TBL] [Abstract][Full Text] [Related]
5. Genetic and epigenetic alterations of familial pancreatic cancers. Brune K; Hong SM; Li A; Yachida S; Abe T; Griffith M; Yang D; Omura N; Eshleman J; Canto M; Schulick R; Klein AP; Hruban RH; Iacobuzio-Donohue C; Goggins M Cancer Epidemiol Biomarkers Prev; 2008 Dec; 17(12):3536-42. PubMed ID: 19064568 [TBL] [Abstract][Full Text] [Related]
6. Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer. Hayashi H; Kohno T; Ueno H; Hiraoka N; Kondo S; Saito M; Shimada Y; Ichikawa H; Kato M; Shibata T; Morizane C; Sakamoto Y; Shimada K; Komatsu Y; Sakamoto N; Okusaka T Pancreas; 2017 Mar; 46(3):335-340. PubMed ID: 28099251 [TBL] [Abstract][Full Text] [Related]
7. KRAS in pancreatic cancer. Agarwal A; Saif MW JOP; 2014 Jul; 15(4):303-5. PubMed ID: 25076326 [TBL] [Abstract][Full Text] [Related]
8. Translational research in pancreatic cancer: KRAS and beyond. Boeck S; Ormanns S; Haas M; Bächmann S; Laubender RP; Siveke JT; Jung A; Kirchner T; Heinemann V Pancreas; 2014 Jan; 43(1):150-2. PubMed ID: 24326376 [No Abstract] [Full Text] [Related]
9. Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4. Masetti M; Acquaviva G; Visani M; Tallini G; Fornelli A; Ragazzi M; Vasuri F; Grifoni D; Di Giacomo S; Fiorino S; Lombardi R; Tuminati D; Ravaioli M; Fabbri C; Bacchi-Reggiani ML; Pession A; Jovine E; de Biase D Cancer Biomark; 2018 Feb; 21(2):323-334. PubMed ID: 29103024 [TBL] [Abstract][Full Text] [Related]
10. Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. Hu HF; Ye Z; Qin Y; Xu XW; Yu XJ; Zhuo QF; Ji SR Acta Pharmacol Sin; 2021 Nov; 42(11):1725-1741. PubMed ID: 33574569 [TBL] [Abstract][Full Text] [Related]
11. Pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and SMAD4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues. Voutsadakis IA; Digklia A Chin Clin Oncol; 2023 Feb; 12(1):2. PubMed ID: 36922358 [TBL] [Abstract][Full Text] [Related]
12. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma. Sinn BV; Striefler JK; Rudl MA; Lehmann A; Bahra M; Denkert C; Sinn M; Stieler J; Klauschen F; Budczies J; Weichert W; Stenzinger A; Kamphues C; Dietel M; Riess H Pancreas; 2014 May; 43(4):578-83. PubMed ID: 24681874 [TBL] [Abstract][Full Text] [Related]
13. Genomic sequencing of key genes in mouse pancreatic cancer cells. Wang Y; Zhang Y; Yang J; Ni X; Liu S; Li Z; Hodges SE; Fisher WE; Brunicardi FC; Gibbs RA; Gingras MC; Li M Curr Mol Med; 2012 Mar; 12(3):331-41. PubMed ID: 22208613 [TBL] [Abstract][Full Text] [Related]
14. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301 [TBL] [Abstract][Full Text] [Related]
15. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors. Berry W; Algar E; Kumar B; Desmond C; Swan M; Jenkins BJ; Croagh D Int J Cancer; 2017 May; 140(10):2331-2343. PubMed ID: 28198009 [TBL] [Abstract][Full Text] [Related]
16. Autophagy, p53, and pancreatic cancer. Iacobuzio-Donahue CA; Herman JM N Engl J Med; 2014 Apr; 370(14):1352-3. PubMed ID: 24693896 [No Abstract] [Full Text] [Related]
17. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. Iacobuzio-Donahue CA; Fu B; Yachida S; Luo M; Abe H; Henderson CM; Vilardell F; Wang Z; Keller JW; Banerjee P; Herman JM; Cameron JL; Yeo CJ; Halushka MK; Eshleman JR; Raben M; Klein AP; Hruban RH; Hidalgo M; Laheru D J Clin Oncol; 2009 Apr; 27(11):1806-13. PubMed ID: 19273710 [TBL] [Abstract][Full Text] [Related]